Pfizer today revised its sales forecast upwards for its COVID-19 vaccine, which it developed with Germany’s BioNTech, by 28.8% to $33.5 billion. The company said the upward revised sales forecast is based on deals signed for 2.1 billion doses this year. The pharmaceutical industry’s previous forecast for $26 billion in May was based on agreements signed for 1.6 billion doses.

Greek-American Albert Bourla, CEO of Pfizer, tweeted: “I believe Q2 was a clear and powerful demonstration of the capabilities of the new @Pfizer. Looking forward, we intend to build upon these successes by continuing to follow the science, trust in our people and remain focused on delivering breakthroughs for the patients we serve.”

$PFE delivered an extremely strong financial performance for Q2. Even excluding direct sales and alliance revenues provided by the Pfizer-BioNTech #COVID19 vaccine, we generated 10% operational revenue growth compared with the prior-year quarter: https://t.co/c6VLpX2knL pic.twitter.com/jfJ8mooCmp

— AlbertBourla (@AlbertBourla) July 28, 2021

We continued to accelerate production and delivery of our #COVID19 vaccine, and we have shipped >1B doses since last December. This is remarkable, especially when you consider that prior to the pandemic, @Pfizer produced ~200M doses annually across our entire Vaccines portfolio. pic.twitter.com/zRfqegeU2u

— AlbertBourla (@AlbertBourla) July 28, 2021

I believe Q2 was a clear and powerful demonstration of the capabilities of the new @Pfizer. Looking forward, we intend to build upon these successes by continuing to follow the science, trust in our people and remain focused on delivering breakthroughs for the patients we serve. pic.twitter.com/F45gRn9Axg

— AlbertBourla (@AlbertBourla) July 28, 2021